Literature DB >> 15914623

Administration of a peptide inhibitor of alpha4-integrin inhibits the development of experimental autoimmune uveitis.

Andrea P Martín1, Luciana Vieira de Moraes, Carlos E Tadokoro, Alessandra G Commodaro, Enrique Urrets-Zavalia, Gabriel A Rabinovich, Julio Urrets-Zavalia, Luiz V Rizzo, Horacio M Serra.   

Abstract

PURPOSE: Recruitment of lymphocytes into the retina and to the vitreous during the development of experimental autoimmune uveitis (EAU) is governed by factors such as the state of activation of inflammatory cells and the repertoire of adhesion molecules expressed by the local vascular endothelia. alpha4 Integrins and their receptors play an important role during homing of cells to the inflammatory site. In the present study, the effect of alpha4-integrin inhibitor on the development of EAU was investigated.
METHODS: EAU was induced either by immunizing B10.RIII mice with the 161-180 peptide or by adoptive transfer of interphotoreceptor retinoid-binding protein (IRBP)-specific uveitogenic T cells. Animals were treated with an active peptide inhibitor (alpha4-api) or a peptide control at different time points after induction of disease. EAU was evaluated by histology 21 to 49 days after immunization. Antigen-specific cell proliferation was evaluated by thymidine incorporation. Cytokine synthesis in culture supernatants and anti-IRBP-specific serum IgG1 and IgG2a were evaluated by ELISA. Delayed-type hypersensitivity was evaluated by ear challenge 2 days before the termination of the experiment.
RESULTS: Treatment with alpha4-api had a significant ameliorating effect on EAU. The anti-IRBP antibody response and cellular proliferation were not affected by the treatment, whereas delayed-type hypersensitivity was significantly diminished. Cytokine synthesis was not changed by treatment, except for a decrease in IL-10 levels.
CONCLUSIONS: The results show that small-molecule inhibitors of alpha4-integrins can act therapeutically in EAU, possibly by interfering with cell adhesion events involved in the development of the disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15914623     DOI: 10.1167/iovs.04-0418

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  11 in total

1.  Autoreactive memory CD4+ T lymphocytes that mediate chronic uveitis reside in the bone marrow through STAT3-dependent mechanisms.

Authors:  Hyun-Mee Oh; Cheng-Rong Yu; Yongjun Lee; Chi-Chao Chan; Arvydas Maminishkis; Charles E Egwuagu
Journal:  J Immunol       Date:  2011-08-10       Impact factor: 5.422

Review 2.  Autoimmune uveitis: clinical, pathogenetic, and therapeutic features.

Authors:  Marcella Prete; Rosanna Dammacco; Maria Celeste Fatone; Vito Racanelli
Journal:  Clin Exp Med       Date:  2015-03-28       Impact factor: 3.984

Review 3.  A look at autoimmunity and inflammation in the eye.

Authors:  Rachel R Caspi
Journal:  J Clin Invest       Date:  2010-09-01       Impact factor: 14.808

Review 4.  Animal models for metabolic, neuromuscular and ophthalmological rare diseases.

Authors:  Guillaume Vaquer; Frida Rivière; Maria Mavris; Fabrizia Bignami; Jordi Llinares-Garcia; Kerstin Westermark; Bruno Sepodes
Journal:  Nat Rev Drug Discov       Date:  2013-03-15       Impact factor: 84.694

5.  Loss of STAT3 in CD4+ T cells prevents development of experimental autoimmune diseases.

Authors:  Xuebin Liu; Yun Sang Lee; Cheng-Rong Yu; Charles E Egwuagu
Journal:  J Immunol       Date:  2008-05-01       Impact factor: 5.422

Review 6.  Role of the retinal vascular endothelial cell in ocular disease.

Authors:  Arpita S Bharadwaj; Binoy Appukuttan; Phillip A Wilmarth; Yuzhen Pan; Andrew J Stempel; Timothy J Chipps; Eric E Benedetti; David O Zamora; Dongseok Choi; Larry L David; Justine R Smith
Journal:  Prog Retin Eye Res       Date:  2012-09-11       Impact factor: 21.198

Review 7.  Experimental autoimmune uveitis and other animal models of uveitis: An update.

Authors:  Svati Bansal; Veluchamy A Barathi; Daiju Iwata; Rupesh Agrawal
Journal:  Indian J Ophthalmol       Date:  2015-03       Impact factor: 1.848

8.  Small-molecule antagonist of VLA-4 (GW559090) attenuated neuro-inflammation by targeting Th17 cell trafficking across the blood-retinal barrier in experimental autoimmune uveitis.

Authors:  Yi Hsing Chen; Malihe Eskandarpour; Xiaozhe Zhang; Grazyna Galatowicz; John Greenwood; Sue Lightman; Virginia Calder
Journal:  J Neuroinflammation       Date:  2021-02-18       Impact factor: 8.322

Review 9.  New pharmacotherapy options for noninfectious posterior uveitis.

Authors:  Uwe Pleyer; Piergiorgio Neri; Christoph Deuter
Journal:  Int Ophthalmol       Date:  2021-02-25       Impact factor: 2.031

10.  An experimental study to evaluate safety/toxicity of intravitreal natalizumab.

Authors:  Rohan Chawla; Madhu Nath; Laxmi Moksha; Tapas C Nag; Thirumurthy Velpandian
Journal:  Indian J Ophthalmol       Date:  2018-10       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.